CN101918453A - 针对活化蛋白c的单克隆抗体 - Google Patents

针对活化蛋白c的单克隆抗体 Download PDF

Info

Publication number
CN101918453A
CN101918453A CN2008801210245A CN200880121024A CN101918453A CN 101918453 A CN101918453 A CN 101918453A CN 2008801210245 A CN2008801210245 A CN 2008801210245A CN 200880121024 A CN200880121024 A CN 200880121024A CN 101918453 A CN101918453 A CN 101918453A
Authority
CN
China
Prior art keywords
antibody
protein
subject
apc
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801210245A
Other languages
English (en)
Chinese (zh)
Inventor
徐俊
查尔斯·埃斯蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Priority to CN201510462991.XA priority Critical patent/CN105153308A/zh
Publication of CN101918453A publication Critical patent/CN101918453A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
CN2008801210245A 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体 Pending CN101918453A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510462991.XA CN105153308A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
US60/983,092 2007-10-26
PCT/US2008/081110 WO2009055669A2 (en) 2007-10-26 2008-10-24 Monoclonal antibodies against activated and unactivated protein c

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2013101082220A Division CN103232541A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体
CN201510462991.XA Division CN105153308A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体

Publications (1)

Publication Number Publication Date
CN101918453A true CN101918453A (zh) 2010-12-15

Family

ID=40289112

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2008801210245A Pending CN101918453A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体
CN2013101082220A Pending CN103232541A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体
CN201510462991.XA Pending CN105153308A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2013101082220A Pending CN103232541A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体
CN201510462991.XA Pending CN105153308A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体

Country Status (13)

Country Link
US (3) US8153766B2 (enExample)
EP (1) EP2205638B1 (enExample)
JP (3) JP2011500843A (enExample)
KR (2) KR101856210B1 (enExample)
CN (3) CN101918453A (enExample)
AU (1) AU2008316661B2 (enExample)
BR (1) BRPI0818865A2 (enExample)
CA (1) CA2703738C (enExample)
IL (2) IL205284A (enExample)
MX (1) MX2010004615A (enExample)
RU (2) RU2539729C2 (enExample)
WO (1) WO2009055669A2 (enExample)
ZA (1) ZA201105704B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302171A (zh) * 2012-03-16 2015-01-21 瑞泽恩制药公司 表达ph敏感性免疫球蛋白序列的非人动物
CN104936618A (zh) * 2012-11-29 2015-09-23 拜尔健康护理有限责任公司 针对活化蛋白c的人源化单克隆抗体及其用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503719WA (en) * 2012-11-29 2015-06-29 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)
TWI673063B (zh) 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白ｃ抗體之出血性疾病的治療
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
WO2017087391A1 (en) * 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
NZ795790A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-BCMA heavy chain-only antibodies
US11970540B2 (en) 2017-06-20 2024-04-30 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
TW201906868A (zh) * 2017-07-07 2019-02-16 日商第一三共股份有限公司 抗蛋白ｃ抗體
WO2019016392A1 (en) 2017-07-20 2019-01-24 Nbe-Therapeutics Ag HUMAN ANTIBODIES BINDING TO ROR2
EP3682247B1 (en) * 2017-09-13 2022-02-09 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
US12319744B2 (en) 2018-09-06 2025-06-03 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)
KR102554477B1 (ko) * 2018-10-18 2023-07-11 오클라호마 메디컬 리써치 화운데이션 질병 활성도의 특징을 규명하는 전신 홍반성 낭창(sle) 질병 활성도 면역 지수를 위한 생체지표
CN109897108B (zh) * 2019-03-11 2021-04-02 上海恒赛生物科技有限公司 抗人内皮蛋白c受体的羊驼单域抗体及应用
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US6989241B2 (en) * 2000-10-02 2006-01-24 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302171A (zh) * 2012-03-16 2015-01-21 瑞泽恩制药公司 表达ph敏感性免疫球蛋白序列的非人动物
CN104936618A (zh) * 2012-11-29 2015-09-23 拜尔健康护理有限责任公司 针对活化蛋白c的人源化单克隆抗体及其用途

Also Published As

Publication number Publication date
CA2703738A1 (en) 2009-04-30
US9127072B2 (en) 2015-09-08
ZA201105704B (en) 2014-05-28
CA2703738C (en) 2018-02-27
BRPI0818865A2 (pt) 2015-05-05
JP2013049694A (ja) 2013-03-14
RU2012150953A (ru) 2014-06-10
AU2008316661A1 (en) 2009-04-30
US20090110683A1 (en) 2009-04-30
US20120164150A1 (en) 2012-06-28
EP2205638A2 (en) 2010-07-14
US20150344588A1 (en) 2015-12-03
KR101856210B1 (ko) 2018-05-09
JP6117741B2 (ja) 2017-04-19
JP2014237651A (ja) 2014-12-18
CN103232541A (zh) 2013-08-07
IL205284A0 (en) 2010-12-30
JP2011500843A (ja) 2011-01-06
IL205284A (en) 2014-06-30
RU2539729C2 (ru) 2015-01-27
MX2010004615A (es) 2010-07-06
WO2009055669A3 (en) 2009-09-03
EP2205638B1 (en) 2017-03-01
AU2008316661B2 (en) 2013-05-23
WO2009055669A2 (en) 2009-04-30
KR20100116166A (ko) 2010-10-29
KR20150092358A (ko) 2015-08-12
US8153766B2 (en) 2012-04-10
IL220622A0 (en) 2012-08-30
RU2010121148A (ru) 2011-12-10
CN105153308A (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
CN101918453A (zh) 针对活化蛋白c的单克隆抗体
US20240092938A1 (en) Compositions for inhibiting masp-2 dependent complement activation
JP2004516236A (ja) 抗血栓剤
AU2016203760B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2013202464B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2015200348B2 (en) Monoclonal antibodies against activated and unactivated protein c
HK1187631A (en) Monoclonal antibodies against activated and unactivated protein c
US20210324058A1 (en) Nedd9 in pulmonary vascular thromboembolic disease
JP2025509185A (ja) 活性化されたタンパク質ｃに対するヒト抗体及びその使用
TW200407427A (en) Human tissue factor antibodies
HK1196070B (en) Compositions for inhibiting masp-2 dependent complement acitivation
HK1196070A (en) Compositions for inhibiting masp-2 dependent complement acitivation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101215